The Ohio State Medical Board voted July 8 to add cachexia, or wasting syndrome, to the list of qualifying conditions for the state’s medical cannabis program, although it rejected adding autism and anxiety, according to a Cincinnati.com report.

The board’s decision follows recommendations from an Ohio State Medical Board committee, which recommended adding cachexia last month, while also rejecting autism and anxiety as new qualifying conditions.

This is the second year in a row that the board has rejected autism and anxiety, arguing that cannabis may do more harm than good for those patients, Cincinnati.com reported.

The board’s decision takes effect immediately and marks the first time a new condition has been added to the program since it launched in 2016, according to the news outlet.